obesity

GLP-1 drugs like Ozempic and Wegovy were originally positioned as treatments for obese patients under medical care. A STAT analysis argues they are now marketed as lifestyle products for consumers seeking weight loss, cosmetic benefits and wellness, with telehealth platforms and direct-to-consumer advertising driving demand far beyond traditional clinical settings.

India has proposed banning the sale of junk food in school canteens and within 50 meters of school premises, a move aimed at curbing rising obesity and diabetes rates among children. The measure would restrict children's access to unhealthy snacks and drinks during the school day. The proposal comes as health officials warn that poor diets are driving childhood health problems, and it has drawn attention to how schools regulate food sold to students.

GLP-1 medications such as Ozempic and Wegovy are being discussed as a new approach to weight loss, moving beyond diet and exercise as the standard advice. Johns Hopkins University is among the institutions weighing in on how these drugs work and what their rise means for obesity treatment. The conversation centers on effectiveness, costs, and how widely these drugs will change care.

Eli Lilly has announced the Lilly Change the Course Commitment, a new initiative aimed at narrowing treatment gaps in diabetes and obesity care in low- and middle-income countries. The pharmaceutical company says the programme will focus on expanding access to treatment where need is greatest. Details on funding and specific country plans have not yet been widely reported.

New research suggests tirzepatide, the weight-loss and diabetes drug sold as Mounjaro and Zepbound, may activate brown fat, a type of tissue that burns calories to generate heat. If confirmed, the finding could help explain the drug's effectiveness and open new avenues in obesity treatment. Coverage is so far limited, with fitness outlets picking up the claim and experts urging caution until results are published in full.

An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.

Major food companies in India are urging regulators to reconsider the red colour proposed for warning labels on packaged foods, Reuters reports. The industry argues the red symbol could stigmatise products, while health advocates support strong front-of-pack warnings to combat rising obesity, diabetes and high salt, sugar and fat consumption in the country.